Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma
Status: Enrolling
Updated:  8/17/2015
Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma
Status: Enrolling
Updated: 8/17/2015
Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma
Status: Enrolling
Updated:  8/17/2015
Bloomington Hospital
mi
from
Bloomington, IN
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma
Status: Enrolling
Updated: 8/17/2015
Bloomington Hospital
mi
from
Bloomington, IN
Click here to add this to my saved trials
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma
Status: Enrolling
Updated:  8/17/2015
St. Joseph Regional Cancer Center
mi
from
Bryan, TX
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma
Status: Enrolling
Updated: 8/17/2015
St. Joseph Regional Cancer Center
mi
from
Bryan, TX
Click here to add this to my saved trials
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of Relapsed Indolent Lymphoma
Status: Enrolling
Updated:  8/17/2015
Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of Relapsed Indolent Lymphoma
Status: Enrolling
Updated: 8/17/2015
Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of Relapsed Indolent Lymphoma
Status: Enrolling
Updated:  8/17/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of Relapsed Indolent Lymphoma
Status: Enrolling
Updated: 8/17/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of Relapsed Indolent Lymphoma
Status: Enrolling
Updated:  8/17/2015
St. Joseph Regional Cancer Center
mi
from
Bryan, TX
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of Relapsed Indolent Lymphoma
Status: Enrolling
Updated: 8/17/2015
St. Joseph Regional Cancer Center
mi
from
Bryan, TX
Click here to add this to my saved trials
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Phase II Trials of CHOP Chemotherapy and Interferon Alpha or Rituximab Anti-CD20 Monoclonal Antibody as Initial Treatment of Patients With Stage III and IV High-Risk Indolent B-Cell Lymphoma and Intermediate Grade B-Cell Lymphoma
Status: Enrolling
Updated:  8/17/2015
Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Phase II Trials of CHOP Chemotherapy and Interferon Alpha or Rituximab Anti-CD20 Monoclonal Antibody as Initial Treatment of Patients With Stage III and IV High-Risk Indolent B-Cell Lymphoma and Intermediate Grade B-Cell Lymphoma
Status: Enrolling
Updated: 8/17/2015
Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated:  8/18/2015
UCLA, Center for Clinical AIDS Research and Education
mi
from
Los Angeles, CA
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated: 8/18/2015
UCLA, Center for Clinical AIDS Research and Education
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated:  8/18/2015
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated: 8/18/2015
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated:  8/18/2015
Siteman Cancer Center at Washington University
mi
from
Saint Louis, MO
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated: 8/18/2015
Siteman Cancer Center at Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated:  8/18/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated: 8/18/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated:  8/18/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated: 8/18/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated:  8/18/2015
Montefiore Medical Center-Einstein Campus
mi
from
Bronx, NY
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated: 8/18/2015
Montefiore Medical Center-Einstein Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated:  8/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma
Status: Enrolling
Updated: 8/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  8/18/2015
University of Chicago Hospitals, Section of Hematology/Oncology
mi
from
Chicago, IL
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 8/18/2015
University of Chicago Hospitals, Section of Hematology/Oncology
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  8/18/2015
Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place
mi
from
St. Louis, MO
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 8/18/2015
Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  8/18/2015
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 8/18/2015
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  8/18/2015
New York Presbyterian Hospital, Weill College of Cornell University
mi
from
New York, NY
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 8/18/2015
New York Presbyterian Hospital, Weill College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  8/18/2015
Morris Cancer Center - Duke University Medical Center, Adult Bone Marrow Transplant Clinic
mi
from
Durham, NC
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 8/18/2015
Morris Cancer Center - Duke University Medical Center, Adult Bone Marrow Transplant Clinic
mi
from
Durham, NC
Click here to add this to my saved trials
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  8/18/2015
Gabrail Cancer Center
mi
from
Canton, OH
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 8/18/2015
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  8/18/2015
Jeane's Hospital of TUHS
mi
from
Philadelphia, PA
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 8/18/2015
Jeane's Hospital of TUHS
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  8/18/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 8/18/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
Beverly Hills, CA
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
Palo Alto, CA
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
Aurora, CO
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
Miami, FL
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
Atlanta, GA
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
Shreveport, LA
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
St Louis, MO
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
Portland, OR
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
Houston, TX
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
Clinical Research Facility
mi
from
San Antonio, TX
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated:  8/20/2015
mi
from
Ottawa,
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Status: Enrolling
Updated: 8/20/2015
mi
from
Ottawa,
Click here to add this to my saved trials
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated:  8/20/2015
The Institute for Drug Development
mi
from
San Antonio, TX
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated: 8/20/2015
The Institute for Drug Development
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated:  8/20/2015
South Texas Accelerated
mi
from
San Antonio, TX
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated: 8/20/2015
South Texas Accelerated
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated:  8/20/2015
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated: 8/20/2015
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease
Status: Enrolling
Updated:  8/21/2015
Children's Oncology Group
mi
from
Arcadia, CA
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease
Status: Enrolling
Updated: 8/21/2015
Children's Oncology Group
mi
from
Arcadia, CA
Click here to add this to my saved trials
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  8/24/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 8/24/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  8/24/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 8/24/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  8/24/2015
CLL Research and Treatment Program
mi
from
New Hyde Park, NY
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 8/24/2015
CLL Research and Treatment Program
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  8/24/2015
New York Presbyterian Hospital-Cornell Medical Center
mi
from
New York, NY
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 8/24/2015
New York Presbyterian Hospital-Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  8/24/2015
The Ohio Sate University
mi
from
Columbus, OH
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 8/24/2015
The Ohio Sate University
mi
from
Columbus, OH
Click here to add this to my saved trials